Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roxithromycin + ambroxol dispersible tablets vs roxithromycin alone for lower respiratory tract infection with viscous sputum
CTR20131242Phase 2Completed
- Sponsor
- Henan Furun Pharmaceutical
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of roxithromycin + ambroxol in pulmonary infection (2 arms), sponsored by Henan Furun Pharmaceutical. Primary endpoints: Antibacterial efficacy rate (Group comparison 1), Expectorant efficacy rate (Group comparison 1) and 2 more. Started Feb 2015; status: completed.
02
Drugs
roxithromycin + ambroxol
03
Conditions
pulmonary infection
Beyond the preview
Go deeper on CTR20131242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131242.